- Home
- NTLA vs VRE Comparison
NTLA vs VRE Comparison
Compare NTLA & VRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- VRE
- Stock Information
- Founded
- NTLA 2014
- VRE 1949
- Country
- NTLA United States
- VRE United States
- Employees
- NTLA N/A
- VRE N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- VRE Real Estate Investment Trusts
- Sector
- NTLA Health Care
- VRE Real Estate
- Exchange
- NTLA Nasdaq
- VRE Nasdaq
- Market Cap
- NTLA 1.2B
- VRE 1.4B
- IPO Year
- NTLA 2016
- VRE 1994
- Fundamental
- Price
- NTLA $25.74
- VRE $14.59
- Analyst Decision
- NTLA Buy
- VRE Buy
- Analyst Count
- NTLA 19
- VRE 5
- Target Price
- NTLA $30.47
- VRE $19.20
- AVG Volume (30 Days)
- NTLA 7.7M
- VRE 708.8K
- Earning Date
- NTLA 11-06-2025
- VRE 10-22-2025
- Dividend Yield
- NTLA N/A
- VRE 2.19%
- EPS Growth
- NTLA N/A
- VRE N/A
- EPS
- NTLA N/A
- VRE N/A
- Revenue
- NTLA $52,857,000.00
- VRE $285,675,000.00
- Revenue This Year
- NTLA $9.20
- VRE $6.48
- Revenue Next Year
- NTLA N/A
- VRE $1.33
- P/E Ratio
- NTLA N/A
- VRE N/A
- Revenue Growth
- NTLA 14.99
- VRE 5.04
- 52 Week Low
- NTLA $5.90
- VRE $13.69
- 52 Week High
- NTLA $26.99
- VRE $18.85
- Technical
- Relative Strength Index (RSI)
- NTLA 84.32
- VRE 39.00
- Support Level
- NTLA $19.89
- VRE $14.37
- Resistance Level
- NTLA $21.49
- VRE $15.20
- Average True Range (ATR)
- NTLA 1.73
- VRE 0.30
- MACD
- NTLA 0.71
- VRE -0.11
- Stochastic Oscillator
- NTLA 86.83
- VRE 14.45
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About VRE Veris Residential Inc.
Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.